DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Phase 2

Recruiting

Conditions: Metastatic Thyroid Cancer

Interventions: Drug: Cyclophosphamide
Drug: Sirolimus

First Posted Date: 2017-04-04

Last Posted Date: 2025-03-12

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 19

Registration Number: NCT03099356

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Phase 1

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Tocilizumab
Procedure: Transcatheter Arterial Chemoembolization

First Posted Date: 2016-12-20

Last Posted Date: 2017-04-25

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02997956

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Interleukin-2
Drug: Nivolumab

First Posted Date: 2016-12-12

Last Posted Date: 2021-07-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 13

Registration Number: NCT02989714

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States

and more 1 locations

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Phase 1

Withdrawn

Conditions: Leukemia, Chronic Myeloid

Interventions: Drug: Nilotinib
Drug: Ruxolitinib

First Posted Date: 2016-11-25

Last Posted Date: 2021-02-16

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02973711

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Vessel Sparing Prostate Radiation Therapy

Phase 2

Completed

Conditions: Cancer of the PROSTATE

Interventions: Radiation: Radiation Therapy

First Posted Date: 2016-11-08

Last Posted Date: 2018-03-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 135

Registration Number: NCT02958787

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Stereotactic Body Radiation Therapy
Procedure: Radical Prostatectomy

First Posted Date: 2016-10-26

Last Posted Date: 2019-11-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 17

Registration Number: NCT02946008

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

Phase 2

Completed

Conditions: Glioma

Interventions: Radiation: High Dose Radiation
Drug: Temozolomide

First Posted Date: 2016-06-17

Last Posted Date: 2021-04-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 26

Registration Number: NCT02805179

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer

Phase 2

Completed

Conditions: Oropharyngeal Squamous Cell Cancer

Interventions: Procedure: Neck Dissection
Procedure: Standard-of-Care (SOC) Transoral Surgery of Primary Site
Radiation: SOC Radiation
Drug: SOC Carboplatin
Drug: SOC Paclitaxel
Procedure: Videofluoroscopy

First Posted Date: 2016-05-27

Last Posted Date: 2023-06-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT02784288

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Genomics in Michigan Impacting Observation or Radiation

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Other: Decipher Prostate Cancer Classifier

First Posted Date: 2016-05-26

Last Posted Date: 2023-09-01

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 356

Registration Number: NCT02783950

Locations: 🇺🇸
Michigan Urological Clinic, Grand Rapids, Michigan, United States
🇺🇸
Urology Surgeons, PC, Grand Rapids, Michigan, United States
🇺🇸
University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States

and more 10 locations

Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

Phase 2

Recruiting

Conditions: Hematopoietic Stem Cell Transplantation

Interventions: Other: Starch Placebo
Drug: Bob's Red Mill®

First Posted Date: 2016-05-05

Last Posted Date: 2024-11-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 105

Registration Number: NCT02763033

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy